Scientific committee

  • Dr. Ulrich Germing
    Dr. Ulrich Germing

    Prof. Germing, vice head of the Department of Haemotology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. His main focus is diagnosis, classification and prognosis of MDS, being trained in cytomorphology by Prof. Aul. He is head of the Düsseldorf MDS registry covering data on more than 5000 patients with MDS and leads the Düsseldorf MDS group since 1999. He participates in international organisations such as The Myelodysplastic Syndromes Foundation and the International Prognostic Working Group in MDS. He is a member of the Clinical Advisory Commitee of the WHO and the European Leukemia Net. As a founder of The German-Austrian-Suisse MDS working group he aims at close collaboration between the different MDS centers. He is author or co-author of more than 220 articles.

  • Dr. John M. Bennett
    Dr. John M. Bennett

    Dr. Bennett is one of the world’s leading authorities on Myelodysplasia and was the founder of the MDS Foundation, as well as editor of the journal Leukemia Research. He is professor emeritus and former head of the medical oncology unit at the University of Rochester Medical Center and was a professor of oncology in medicine, pathology and laboratory medicine at the University of Rochester Medical School. He is serving, currently, as an attending Hematopathologist in the hematopathology Section of the Department of Pathology at University of Rochester Medical Center.

  • Dr. Francesc Sole
    Dr. Francesc Sole

    Dr. Francesc Solé, from Barcelona (Spain), is an authority on Cytogenetics in Myelodysplasia (MDS). He was involved in the development of IPSS-R and is a member of the Steering Committee of IWG-PM (MDS Foundation). From 1996 until 2008, Dr. Solé was the coordinator of the Spanish Cytogenetics in Hematology Working Group. From 2004 until 2012 he was a member of the Steering Committee of Hematologic Quality Control in Eurogenest. Currently, he is the Scientific Director of the Institut de la Recerca contra la Leucèmia Josep Carreras-Campus ICO-GTiP, where he is also the Director of the Cytogenetic Platform Group and of the MDS Group. Dr. Solé holds Adjunct Professor positions at the Universitat Pompeu Fabra (Barcelona) and Universitat Autònoma de Barcelona (Bellaterra). He has published more than 200 papers. As a principal investigator he has coordinated 37 projects and has been involved in 82 collaborations.

  • Dr. Detlef Haase
    Dr. Detlef Haase

    Prof. Haase is the Director of the Tumorcytogenetic Laboratory and of the Laboratory for Specialised Haematologic Diagnostics at the Department of Haemotology and Oncology, Georg-August-University of Göttingen, Germany. He participates in many international organisations such as The Myelodysplastic Syndromes Foundation, the International Cytogenetics Working Group and the International Prognostic Working Group in MDS (Co Chairman). He is a member of the European Leukemia Net Steering Committee and lead participant of it´s WP 11 (Cytogenetics). He is author or co-author of over 130 articles in international peer-reviewed journals and reviewer for scientific journals like Blood, Leukemia, Haematologica, Genes Chromosomes and Cancer, Leukemia Research and Annals of Hematology.

  • Dr. Raphael Itzykson
    Dr. Raphael Itzykson

    Dr Itzykson is a physician-scientist working in the Hematology Department of Hopital Saint-Louis, Paris, France. His research focuses on the clinical and molecular prognostic factors of MDS, and on the pathogenesis of CMML. He has published articles in several peer-reviewed journals including Blood, Leukemia, Journal of Clinical Oncology and Haematologica.

  • Dr. Leonie Saft
    Dr. Leonie Saft

    Leonie Saft, M.D., Ph.D. is a specialist (consultant) in clinical pathology & cytology, and head of the Hematopathology and Flow cytometry Section at the Department of Pathology, Karolinska University Hospital, Solna, Stockholm, Sweden. She is member of the Nordic MDS Research Group and performs central review of Bone Marrow Biopsies within Nordic clinical MDS trials and participates in International Organisations such as the European Leukemia Network group (ELN) and the European Bone Marrow Study Group (EBMG).

  • Dr. Arjan van de Loosdrecht
    Dr. Arjan van de Loosdrecht

    Prof Arjan van de Loosdrecht is a professor of hematology at the department of Hematology, VUmc, Amsterdam. At the VUmc he is chair of the Scientific Committee (CWO) of the Cancer Center Amsterdam. He is author of over 160 peer-reviewed papers published in national and international journals particularly in the field of hematology (myeloid malignancies) and immunology. His particular scientific experiences and interests are on translational hematology. He is project leader/principle investigator of clinical (translational) programs dealing with the treatment of low-intermediate risk MDS. In addition, research focus on the role of flow cytometry in the diagnosis, prognostication and monitoring of MDS. He is chair of the working group MDS of the Dutch Society of Cytometry on the implementation of flowcytometry in MDS and initiated a platform within the ELN on the implementation of flowcytometry in MDS in Europe.

  • Dr. Alan F. List
    Dr. Alan F. List

    Dr. Alan List is the President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.

  • Dr. Esther Oliva
    Dr. Esther Oliva

    Esther Natalie Oliva earned degrees in Medicine and Surgery from the University of Messina, Italy, in 1990. In 1994, she received a degree in General Hematology from the same university. From 1991 to 1997, she earned a Mario Negri Institute research grant to conduct research at the Nephrology Unit of the Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" in Reggio Calabria, Italy. Since 1998 she has been a practicing haematologist at the Haematology Unit of the same hospital in Reggio Calabria, in charge of the Myelodysplastic Syndromes, Aplastic Anemia and Anemia section. Dr Oliva has developed a unique instrument, QOL-E, for the evaluation of quality of life in myelodysplastic syndromes. She has also developed and coordinated clinical trials in pharmacological research in hematology with a special focus on myelodysplastic syndromes, acute myeloid leukemia and on quality of life. She is the chair of the non-profit Association QOL-ONE for research on quality of life in Hematological patients. From 2015 she is the Chair of the EHA Scientific Working Group Quality of Life and Symptoms. In 2017 Dr. Oliva is an examiner for the EHA European Hematology Passport. She is an active member of the American Society of Hematology, the European Haematology Association, the International Society of Quality of Life and the Italian Society of Hematology and editor of the following Journals: American Journal of Blood Research and Clinical Reviews and Opinions.

  • Dr. Michael Pfeilstöcker
    Dr. Michael Pfeilstöcker

    Dr. Michael Pfeilstöcker is consultant at the Third Department for Internal Medicine – Hematology/Oncology, Hanusch Hospital, Vienna, Austria, where he also started a research career within the framework of the associated Institute for Leukemia Research now part of the Cluster Oncology of the L. Boltzmann Society. His research interests include theoretical and clinical studies in patients with myelodysplastic syndromes. A main focus of his research is in classification problems and prognostic factors in MDS. Furthermore, he is involved in clinical trials on new drugs in MDS including iron chelators. He is associate professor for medicine at the Vienna Medical University and chairs the MDS working group of the Austrian Society of Hematology and Oncology, which has established a fruitful ongoing international collaboration. He has authored numerous articles in peer-reviewed journals including Blood and Leukemia and is a member of several professional organizations, including the American Society of Hematology.

  • Dr. Guido Kobbe
    Dr. Guido Kobbe

    Professor Kobbe is the head of the hematopoietic stem cell transplant program of the Department of Hematology, Oncology and Clinical Immunology at the University Hospital of the Heinrich Heine University Düsseldorf, Germany. His focus is allogeneic blood stem cell transplantation in MDS, Acute Leukemia and malignant Lymphoma and Myeloma. As a member of the Düsseldorf MDS research group he has a special interest in improving treatment results of allogeneic blood stem cell transplantation in patients with MDS. This includes the identification of suitable patients, design of transplant protocols and the prevention, detection and treatment of relapse. With a focus on clinical research he has authored and co-authored more than 150 peer reviewed articles.

  • Dr. Rafael Bejar
    Dr. Rafael Bejar

    Dr. Rafael Bejar is a physician-scientist at the UCSD Moores Cancer in La Jolla, California. After earning a BS in physics at the Massachusetts Institute of Technology, Dr. Bejar enrolled in the Medical Scientist Training Program at UCSD where he received his PhD and MD degrees. His internship in internal medicine was at the University of Chicago before moving to Boston where he completed his residency, and later a Chief Resident year at the Brigham and Women’s Hospital. Dr. Bejar’s hematology and oncology fellowship was at the Dana-Farber Cancer Institute where he began his research into the genetic basis of myelodysplastic syndromes. His work has helped identify how genetic mutations contribute to the development of MDS and how testing for these abnormalities can help physicians care for their patients with this disease. He is a writing member of the NCCN guidelines committee for MDS and is a member of the International Working Group for MDS molecular prognosis committee. Dr. Bejar has established an MDS Center of Excellence at UCSD where he cares for patients and continues to study the molecular mechanisms that drive the development of MDS.

  • Dr. Sophia Park
    Dr. Sophia Park

    Sophie PARK is Head of the MDS Clinical and Fundamental Research Program at Grenoble Alpes Hospital, Grenoble, France. She obtained her medical degree from Paris V René Descartes University, Cochin Hospital, Paris, before completing her residency in Hematology at the Assistance Publique des Hôpitaux de Paris, France. Professor Sophie PARK’s primary research focuses on MDS, treatment by erythropoiesis stimulating agents, AML, and basic research on the niche in MDS. She has conducted several controlled, prospective multicentre studies that focus on AML, lower- risk MDS, ESA and iron chelation. She has published about 70 original articles in international peer-reviewed journals. And has delivered numerous lectures at local, national, and international conferences and symposia.

  • Dr. Blanca Xicoy
    Dr. Blanca Xicoy

    Dr. Blanca Xicoy is a Senior Hematologist, working in the Clinical Hematology Department from Institut Català d’Oncologia-Hospital Germans Trias i Pujol in Badalona (Barcelona). Among her activities it should be highlighted first, clinical activity focused on chronic myeloproliferative neoplasms and marrow insufficiencies (myelodysplastic syndromes and medullary aplasia); second, research activity in these diseases as principal investigator of phase 2 to 4 clinical trials and collaboration in public and private research projects; third, active participation in national cooperative groups of these diseases (Spanish Group of Chronic Myeloid Leukemia, Spanish Group of Philadelphia Negative Chronic Myeloproliferative Neoplasms, Spanish Group of Myelodysplastic Syndromes) developing clinical guidelines of diagnosis and treatment of such diseases; fourth, one-year stay (2013-2014) at the Heinrich-Heine Universitäts-Klinikum, Düsseldorf, where the Düsseldorf MDS registry is located; fifth, active collaboration with the Josep Carreras Leukemia Research Institute collecting samples for the biobank as well as principal investigator and co-investigator from research projects within this institution; and sixth, Post-grade and Master in statistics in health sciences. As a result, she is author or co-author of more than 75 papers published in peer-review national and international journals.

  • Dr. Lucy A. Godley
    Dr. Lucy A. Godley

    Lucy A. Godley, MD, PhD, is an expert in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas and multiple myeloma. She also cares for patients undergoing stem cell transplantation and patients with benign hematologic conditions. Dr. Godley has a special interest in the molecular basis of bone marrow malignancies and is an active researcher in the field. In her laboratory, Dr. Godley studies the basis for cancer cells' abnormal patterns of DNA methylation, as well as inherited forms of bone marrow cancers. She has received numerous awards for her research, including the Howard Hughes Medical Institute Physician Postdoctoral Award, the Cancer and Leukemia Group B (CALGB) Foundation Clinical Research Award, the American Society of Clinical Oncology Young Investigator Award, the Cancer Research Foundation Young Investigator Award, the Schweppe Foundation Career Development Award and the Kimmel Scholar Award. She was inducted into the American Society of Clinical Investigation in 2012. Dr. Godley's goal is to improve health through a deeper understanding and appreciation of science by integrating knowledge about fundamental networks within cancer cells and by bringing novel insights into the pathophysiology of her patients' diseases while offering them new treatment options.